Loading...

We've got a brand new version of Simply Wall St! Try it out

Arcadia Biosciences

Nasdaq:RKDA
Snowflake Description

Flawless balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
RKDA
Nasdaq
$37M
Market Cap
  1. Home
  2. US
  3. Food, Beverage & Tobacco
Company description

Arcadia Biosciences, Inc., an agricultural food ingredient company, develops and commercializes health and nutrition ingredient traits worldwide. The last earnings update was 13 days ago. More info.


Add to Portfolio Compare Print
  • Arcadia Biosciences has significant price volatility in the past 3 months.
RKDA Share Price and Events
7 Day Returns
2.9%
NasdaqCM:RKDA
1.5%
US Food
0.7%
US Market
1 Year Returns
12.1%
NasdaqCM:RKDA
3.7%
US Food
13.7%
US Market
RKDA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Arcadia Biosciences (RKDA) 2.9% -15.8% -38.8% 12.1% -83% -
US Food 1.5% 2.2% 0.5% 3.7% -6.1% 20.3%
US Market 0.7% 4.7% 6.1% 13.7% 39.2% 44.5%
1 Year Return vs Industry and Market
  • RKDA outperformed the Food industry which returned 3.7% over the past year.
  • RKDA underperformed the Market in United States of America which returned 13.7% over the past year.
Price Volatility
RKDA
Industry
5yr Volatility vs Market

Value

 Is Arcadia Biosciences undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Arcadia Biosciences. This is due to cash flow or dividend data being unavailable. The share price is $4.26.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Arcadia Biosciences's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Arcadia Biosciences's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqCM:RKDA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in USD $-4.30
NasdaqCM:RKDA Share Price ** NasdaqCM (2019-11-18) in USD $4.26
United States of America Food Industry PE Ratio Median Figure of 41 Publicly-Listed Food Companies 24.8x
United States of America Market PE Ratio Median Figure of 2,924 Publicly-Listed Companies 18.25x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Arcadia Biosciences.

NasdaqCM:RKDA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:RKDA Share Price ÷ EPS (both in USD)

= 4.26 ÷ -4.30

-0.99x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Arcadia Biosciences is loss making, we can't compare its value to the US Food industry average.
  • Arcadia Biosciences is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Arcadia Biosciences's expected growth come at a high price?
Raw Data
NasdaqCM:RKDA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.99x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
29.9%per year
United States of America Food Industry PEG Ratio Median Figure of 27 Publicly-Listed Food Companies 1.28x
United States of America Market PEG Ratio Median Figure of 2,038 Publicly-Listed Companies 1.46x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Arcadia Biosciences, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Arcadia Biosciences's assets?
Raw Data
NasdaqCM:RKDA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in USD $1.57
NasdaqCM:RKDA Share Price * NasdaqCM (2019-11-18) in USD $4.26
United States of America Food Industry PB Ratio Median Figure of 70 Publicly-Listed Food Companies 2.31x
United States of America Market PB Ratio Median Figure of 5,086 Publicly-Listed Companies 1.76x
NasdaqCM:RKDA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:RKDA Share Price ÷ Book Value per Share (both in USD)

= 4.26 ÷ 1.57

2.72x

* Primary Listing of Arcadia Biosciences.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Arcadia Biosciences is overvalued based on assets compared to the US Food industry average.
X
Value checks
We assess Arcadia Biosciences's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Food industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Food industry average (and greater than 0)? (1 check)
  5. Arcadia Biosciences has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Arcadia Biosciences expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
29.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Arcadia Biosciences expected to grow at an attractive rate?
  • Unable to compare Arcadia Biosciences's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Arcadia Biosciences's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • Arcadia Biosciences's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqCM:RKDA Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqCM:RKDA Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 29.9%
NasdaqCM:RKDA Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 123.1%
United States of America Food Industry Earnings Growth Rate Market Cap Weighted Average 19.7%
United States of America Food Industry Revenue Growth Rate Market Cap Weighted Average 2.9%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14.4%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqCM:RKDA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqCM:RKDA Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 27 -12 2
2020-12-31 9 -19 3
2019-12-31 2 -27 1
2019-11-19
NasdaqCM:RKDA Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-09-30 1 -15 -23
2019-06-30 1 -15 -5
2019-03-31 1 -15 -15
2018-12-31 1 -14 -13
2018-09-30 2 -14 -16
2018-06-30 3 -12 -25
2018-03-31 3 -12 -22
2017-12-31 4 -14 -16
2017-09-30 3 -16 -18
2017-06-30 4 -17 -18
2017-03-31 3 -17 -19
2016-12-31 3 -17 -20

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Arcadia Biosciences is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Arcadia Biosciences's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqCM:RKDA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Arcadia Biosciences Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:RKDA Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 -0.95 -0.58 -1.31 2.00
2020-12-31 -2.10 -1.84 -2.54 3.00
2019-12-31 -4.27 -4.27 -4.27 1.00
2019-11-19
NasdaqCM:RKDA Past Financials Data
Date (Data in USD Millions) EPS *
2019-09-30 -4.30
2019-06-30 -0.94
2019-03-31 -3.51
2018-12-31 -3.58
2018-09-30 -5.09
2018-06-30 -10.15
2018-03-31 -10.29
2017-12-31 -7.28
2017-09-30 -8.47
2017-06-30 -8.23
2017-03-31 -8.40
2016-12-31 -8.85

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Arcadia Biosciences will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Arcadia Biosciences's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Arcadia Biosciences has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Arcadia Biosciences performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Arcadia Biosciences's growth in the last year to its industry (Food).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Arcadia Biosciences does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Arcadia Biosciences's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Arcadia Biosciences's 1-year growth to the US Food industry average as it is not currently profitable.
Earnings and Revenue History
Arcadia Biosciences's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Arcadia Biosciences Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:RKDA Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 1.20 -23.21 13.46
2019-06-30 1.18 -4.57 11.99
2019-03-31 1.41 -15.48 11.80
2018-12-31 1.46 -13.48 11.60
2018-09-30 2.45 -15.79 10.82
2018-06-30 2.67 -24.77 10.23
2018-03-31 3.22 -22.11 10.22
2017-12-31 4.03 -15.71 10.65
2017-09-30 3.14 -18.46 10.58
2017-06-30 3.62 -18.11 10.85
2017-03-31 3.35 -18.65 10.67
2016-12-31 3.19 -19.62 11.05
2016-09-30 3.99 -17.77 11.76
2016-06-30 4.74 -18.22 11.89
2016-03-31 5.45 -18.22 11.92
2015-12-31 5.41 -20.73 11.12
2015-09-30 6.87 -20.51 10.53
2015-06-30 6.55 -24.52 9.68
2015-03-31 6.42 -26.30 10.88
2014-12-31 6.98 -22.08 10.13
2014-09-30 6.19 -21.31 9.83
2014-06-30 6.51 -16.40 9.81
2014-03-31 6.53 -13.37 7.84
2013-12-31 6.48 -13.20 7.97
2012-12-31 7.01 -12.37 8.28

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Arcadia Biosciences has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Arcadia Biosciences has efficiently used its assets last year compared to the US Food industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Arcadia Biosciences improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Arcadia Biosciences's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Food industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Arcadia Biosciences has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Arcadia Biosciences's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Arcadia Biosciences's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Arcadia Biosciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Arcadia Biosciences's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Arcadia Biosciences's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 245.3x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Arcadia Biosciences Company Filings, last reported 1 month ago.

NasdaqCM:RKDA Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 14.23 0.14 30.90
2019-06-30 8.29 0.00 20.03
2019-03-31 0.63 0.00 17.79
2018-12-31 12.82 0.00 21.82
2018-09-30 12.92 0.00 24.60
2018-06-30 8.13 0.00 28.60
2018-03-31 0.67 0.00 20.42
2017-12-31 8.01 0.00 13.02
2017-09-30 10.67 0.00 15.70
2017-06-30 14.76 25.23 44.18
2017-03-31 18.37 25.18 48.53
2016-12-31 22.20 25.13 50.56
2016-09-30 27.51 25.08 53.89
2016-06-30 31.29 25.03 54.23
2016-03-31 35.48 24.98 50.19
2015-12-31 40.23 24.93 50.24
2015-09-30 43.83 23.10 74.26
2015-06-30 47.93 22.81 80.00
2015-03-31 -7.30 12.95 11.28
2014-12-31 -1.89 14.48 16.57
2014-09-30 -0.29 14.54 21.17
2014-06-30 6.75 14.27 25.68
2014-03-31 -17.30 14.56 2.84
2013-12-31 -17.30 14.49 2.84
2012-12-31 -5.68 8.00 5.35
  • Arcadia Biosciences's level of debt (1%) compared to net worth is satisfactory (less than 40%).
  • Arcadia Biosciences had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Arcadia Biosciences has sufficient cash runway for 1.9 years based on current free cash flow.
  • Arcadia Biosciences has sufficient cash runway for 2 years if free cash flow continues to reduce at historical rates of -5.4% each year.
X
Financial health checks
We assess Arcadia Biosciences's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Arcadia Biosciences has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Arcadia Biosciences's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Arcadia Biosciences dividends.
If you bought $2,000 of Arcadia Biosciences shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Arcadia Biosciences's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Arcadia Biosciences's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqCM:RKDA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
United States of America Food Industry Average Dividend Yield Market Cap Weighted Average of 29 Stocks 2.8%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1956 Stocks 2.3%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqCM:RKDA Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2021-12-31
2020-12-31
2019-12-31
2019-11-19

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Arcadia Biosciences has not reported any payouts.
  • Unable to verify if Arcadia Biosciences's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Arcadia Biosciences's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Arcadia Biosciences has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Arcadia Biosciences's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Arcadia Biosciences afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Arcadia Biosciences has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Arcadia Biosciences's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Matt Plavan
COMPENSATION $583,010
AGE 55
TENURE AS CEO 0.2 years
CEO Bio

Mr. Matthew T. Plavan, also known as Matt, serves as President, Chief Executive Officer and Director of Arcadia Biosciences, Inc. since September 1, 2019. He had been President of Arcadia Specialty Genomics since February 2019 and also had been Chief Financial Officer of Arcadia Biosciences, Inc. since September 12, 2016 until September 1, 2019. Mr. Plavan served as Secretary at Arcadia Biosciences, Inc. until 2019 Mr. Plavan served as an Advisor of Cesca Therapeutics Inc. since October 29, 2014. He served as the Chief Executive Officer of Cesca Therapeutics Inc. from January 30, 2012 to October 28, 2014 and served as its Executive Vice President of Business Development from September 2008 to January 2012, Principal Accounting Officer until January 2012, Chief Financial Officer from 2005 to March 27, 2013, Chief Operating Officer from 2008 to 2010 and Interim Chief Executive Officer from December 2008 to April 2009. Mr. Plavan has many years of financial leadership, P&L responsibility and general management experience. He served as the Chief Financial Officer for Reason Inc., from 2000 to 2002. Mr. Plavan served as the Chief Financial Officer of StrionAir, Inc. from 2002 to 2005. From 1993 to 2000, he served in key financial and operating leadership roles within McKesson and McKesson-acquired companies, including Vice President of Finance for a $300 million division, iMcKesson. For three years as the Senior Director of Investor Relations and International Corporate Development at Access Health, Inc. (before being acquired by McKesson in 1998), Mr. Plavan oversaw the day-to-day investor relations affairs. He was an Audit Manager in the Audit and Risk Advisory Services group of Ernst & Young LLP overseeing audits and providing accounting consulting services for a number of publicly held audit clients. Mr. Plavan served as a Director of Cesca Therapeutics Inc. from January 2012 to June 19, 2015. He became a Certified Public Accountant in 1992. Mr. Plavan holds a Bachelor of Arts in Business Economics from the University of California at Santa Barbara.

CEO Compensation
  • Matt's compensation has increased whilst company is loss making.
  • Matt's remuneration is about average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Arcadia Biosciences management team in years:

0.6
Average Tenure
53
Average Age
  • The average tenure for the Arcadia Biosciences management team is less than 2 years, this suggests a new team.
Management Team

Matt Plavan

TITLE
President
COMPENSATION
$583K
AGE
55
TENURE
0.2 yrs

Sarah Reiter

TITLE
Chief Commercial Officer
COMPENSATION
$783K
AGE
47
TENURE
1.7 yrs

Pam Haley

TITLE
Chief Financial Officer
TENURE
0.2 yrs

Randy Shultz

TITLE
Head of Research & Development
TENURE
0.6 yrs

Zhongjin Lu

TITLE
Director of Product Development
COMPENSATION
$320K
AGE
53
TENURE
9.8 yrs
Board of Directors Tenure

Average tenure and age of the Arcadia Biosciences board of directors in years:

1.8
Average Tenure
57.5
Average Age
  • The average tenure for the Arcadia Biosciences board of directors is less than 3 years, this suggests a new board.
Board of Directors

Kevin Comcowich

TITLE
Chairman of the Board
COMPENSATION
$162K
AGE
50
TENURE
2 yrs

Matt Plavan

TITLE
President
COMPENSATION
$583K
AGE
55
TENURE
0.2 yrs

Greg Waller

TITLE
Independent Director
COMPENSATION
$93K
AGE
69
TENURE
2.4 yrs

Amy Yoder

TITLE
Independent Director
COMPENSATION
$91K
AGE
52
TENURE
2.3 yrs

Vicki Chandler

TITLE
Member of Scientific Advisory Board

Luca Comai

TITLE
Member of Scientific Advisory Board

Peter Quail

TITLE
Member of Scientific Advisory Board

Lilian Murray

TITLE
Independent Director
COMPENSATION
$92K
AGE
60
TENURE
1.4 yrs

Al Bolles

TITLE
Independent Director
COMPENSATION
$119K
AGE
61
TENURE
1.5 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Arcadia Biosciences individual insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
23. Sep 19 Buy Matthew Plavan Individual 23. Sep 19 23. Sep 19 2,000 $5.25 $10,500
17. Sep 19 Buy Kevin Comcowich Individual 17. Sep 19 17. Sep 19 5,000 $5.88 $29,388
10. Sep 19 Buy Matthew Plavan Individual 10. Sep 19 10. Sep 19 2,000 $6.52 $13,014
10. Sep 19 Buy Sarah Reiter Individual 10. Sep 19 10. Sep 19 1,200 $6.48 $7,776
10. Sep 19 Buy Kevin Comcowich Individual 10. Sep 19 10. Sep 19 15,000 $6.49 $97,333
28. Aug 19 Buy Matthew Plavan Individual 26. Aug 19 28. Aug 19 8,000 $9.32 $69,860
X
Management checks
We assess Arcadia Biosciences's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Arcadia Biosciences has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Do Institutions Own Arcadia Biosciences, Inc. (NASDAQ:RKDA) Shares?

With a market capitalization of US$42m, Arcadia Biosciences is a small cap stock, so it might not be well known by many institutional investors. … View our latest analysis for Arcadia Biosciences NasdaqCM:RKDA Ownership Summary, August 19th 2019 What Does The Institutional Ownership Tell Us About Arcadia Biosciences? … Private Company Ownership Our data indicates that Private Companies hold 18%, of the company's shares.

Simply Wall St -

Why Arcadia Biosciences, Inc.'s (NASDAQ:RKDA) CEO Pay Matters To You

This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. … See our latest analysis for Arcadia Biosciences How Does Raj Ketkar's Compensation Compare With Similar Sized Companies? … Given the total loss of 93% over three years, many shareholders in Arcadia Biosciences, Inc.

Simply Wall St -

How Many Arcadia Biosciences, Inc. (NASDAQ:RKDA) Shares Do Institutions Own?

Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable percentage of the smaller ones. … We also tend to see lower insider ownership in companies that were previously publicly owned. … With a market capitalization of US$31m, Arcadia Biosciences is a small cap stock, so it might not be well known by many institutional investors.

Simply Wall St -

Did Changing Sentiment Drive Arcadia Biosciences's Share Price Down A Painful 89%?

Arcadia Biosciences isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. … As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth. … Over the last three years, Arcadia Biosciences's revenue dropped 29% per year.

Simply Wall St -

What does Arcadia Biosciences, Inc.'s (NASDAQ:RKDA) Balance Sheet Tell Us About Its Future?

(NASDAQ:RKDA), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. … Is RKDA right in choosing financial flexibility over lower cost of capital … There are well-known benefits of including debt in capital structure, primarily a lower cost of capital.

Simply Wall St -

Should You Be Pleased About The CEO Pay At Arcadia Biosciences Inc's (NASDAQ:RKDA)

This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. … How Does Raj Ketkar's Compensation Compare With Similar Sized Companies. … Our data indicates that Arcadia Biosciences Inc is worth US$20m, and total annual CEO compensation is US$644k.

Simply Wall St -

What Investors Should Know About Arcadia Biosciences Inc's (NASDAQ:RKDA) Financial Strength

Arcadia Biosciences Inc (NASDAQ:RKDA), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. … However, the trade-off is RKDA will have to follow strict debt obligations which will reduce its financial flexibility. … Is financial flexibility worth the lower cost of capital.

Simply Wall St -

Who Are The Major Shareholders In Arcadia Biosciences Inc (NASDAQ:RKDA)?

In this article, I will take a quick look at Arcadia Biosciences Inc’s (NASDAQ:RKDA) recent ownership structure – an unconventional investing subject, but an important one. … Ownership structure has been found to have an impact on shareholder returns in both short- and long-term. … The implications of these institutions’ actions can either benefit or hinder individual investors, so it is important to understand the ownership composition of your stock investment.

Simply Wall St -

Will Arcadia Biosciences Inc (NASDAQ:RKDA) Need To Raise More Money?

Given that Arcadia Biosciences is spending more money than it earns, it will need to fund its expenses via external sources of capital. … NasdaqCM:RKDA Income Statement May 9th 18 When will Arcadia Biosciences need to raise more cash? … However, if Arcadia Biosciences continues to grow its opex at this rate, given how much money it currently has in the bank, it will need to raise capital again in 1.2 years.

Simply Wall St -

Want To Invest In Arcadia Biosciences Inc (NASDAQ:RKDA)? Here's How It Performed Lately

See our latest analysis for Arcadia Biosciences How Well Did RKDA Perform? … For Arcadia Biosciences, its latest trailing-twelve-month earnings is -US$18.45M, which, in comparison to the prior year's figure, has become more negative. … Each year, for the past five years Arcadia Biosciences has seen an annual decline in revenue of -17.41%, on average.

Simply Wall St -

Company Info

Description

Arcadia Biosciences, Inc., an agricultural food ingredient company, develops and commercializes health and nutrition ingredient traits worldwide. The company offers a suite of agricultural productivity traits, including nitrogen use efficiency, water use efficiency and drought tolerance, salinity tolerance, and Wheat Yield traits. It also provides nutritional oils comprising gamma linolenic acid safflower oil to manufacturers of dietary and nutritional supplements, medical foods, dog food, and other products under the SONOVA brand. In addition, the company has various programs under development comprising fiber resistant starch wheat, whole grain flour, and reduced gluten wheat programs. Arcadia Biosciences, Inc. has strategic collaborations with Corteva Agriscience and Ardent Mills LLC to develop and commercialize wheat varieties. The company was founded in 2002 and is headquartered in Davis, California.

Details
Name: Arcadia Biosciences, Inc.
RKDA
Exchange: NasdaqCM
Founded: 2002
$36,832,594
8,646,149
Website: http://www.arcadiabio.com
Address: Arcadia Biosciences, Inc.
202 Cousteau Place,
Suite 105,
Davis,
California, 95618,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM RKDA Common Stock Nasdaq Capital Market US USD 15. May 2015
DB 17DN Common Stock Deutsche Boerse AG DE EUR 15. May 2015
Number of employees
Current staff
Staff numbers
44
Arcadia Biosciences employees.
Industry
Agricultural Products
Food, Beverage & Tobacco
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/11/19 00:41
End of day share price update: 2019/11/18 00:00
Last estimates confirmation: 2019/11/07
Last earnings filing: 2019/11/06
Last earnings reported: 2019/09/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.